Mylan unveils generic Avodart Capsules for treating benign prostatic hyperplasia in men in the US.
M2 PHARMA-June 27, 2016-Mylan unveils generic Avodart Capsules for treating benign prostatic hyperplasia in men in the US
(C)2016 M2 COMMUNICATIONS
Pharmaceutical company Mylan NV(Nasdaq:MYL) TASE:MYL) revealed on Friday the availability of Dutasteride Capsules, 0.5 mg in the US market.
The company said Dutasteride Capsules, 0.5 mg is the generic version of GlaxoSmithKline's Avodart Capsules.
In conjunction, the company has receivred final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Dutasteride Capsules, 0.5 mg.
Dutasteride Capsules are reportedly indicated as monotherapy for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention and reduce the risk of the need for BPH-related surgery. It may be used with tamsulosin for the treatment of symptomatic BPH in men with an enlarged prostate.
For the 12 months ending 30 April 2016, Dutasteride Capsules, 0.5 mg, had US sales of approximately USD297.2m, according to IMS Health.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Jun 27, 2016|
|Previous Article:||Jazz Pharmaceuticals reports expiration of HSR Waiting Period for planned acquisition of Celator Pharmaceuticals.|
|Next Article:||Vitrolife Launches EmbryoScope+ Time-Lapse System.|